Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.45 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.45 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.45 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24351449 | 0.84 | SYK (0.45) | KDM4EALDH1A1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL5723357 | 0.81 | MKNK1 (0.48) | KDM4EALDH1A1TSHRSIGMAR1MKNK1 | |
| SCHEMBL24714753 | 0.81 | GUCY1B2 (0.45) | KDM4EALDH1A1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL27002892 | 0.77 | KDM4E (0.60) | KDM4EALDH1A1TSHRSIGMAR1NPC1 | |
| SCHEMBL29338269 | 0.76 | POLB (0.51) | KDM4EALDH1A1TSHRSIGMAR1NPC1 | |
| SCHEMBL2816992 | 0.75 | LMNA (0.45) | KDM4EALDH1A1TSHRSIGMAR1NPC1 | |
| SCHEMBL13550155 | 0.75 | CXCR4 (0.66) | KDM4EALDH1A1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL13718466 | 0.75 | MTOR (0.52) | KDM4EALDH1A1TSHRSIGMAR1NPC1 | |
| SCHEMBL5723777 | 0.74 | NR3C1 (0.43) | KDM4ETSHRSIGMAR1MEN1KMT2A | |
| SCHEMBL7300773 | 0.72 | TSHR (0.57) | KDM4EALDH1A1TSHRSIGMAR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| CN-113302183-A | Cyclic ureas | 圣瑞诺有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20190345138-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| EP-3541813-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018092089-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018092089-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345138-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | KDM4E 635/4885ALDH1A1 1319/4885GUCY1B2 1749/4885 |
| US-20210292305-A1 | Cyclic Ureas | RIPK1, RIPK3, RIPK4 | KDM4E 3602/4885ALDH1A1 3997/4885GUCY1B2 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.